Association of Anticoagulation and Major Adverse Limb Events After Index Peripheral Endovascular Intervention

• Published in: The American journal of cardiology 2023-04, Vol.192, p.124-131
• Main Authors: Ramkumar, Niveditta, Goodney, Philip P., Creager, Mark A., Henkin, Stanislav
• Format: Article
• Language: English
• Subjects: Amputation; Angioplasty; Anticoagulants; Anticoagulants - adverse effects; Cardiac arrhythmia; Cardiovascular disease; Cardiovascular system; Endovascular Procedures; Humans; Intervention; Ischemia; Male; Males; Mortality; Occlusion; Patients; Peripheral Arterial Disease; Retrospective Studies; Risk; Risk Factors; Statistical analysis; Treatment Outcome; Vascular diseases; Vascular Patency; Vein & artery diseases
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2023.01.030

Dual-antiplatelet therapy is commonly prescribed after endovascular intervention for peripheral artery disease. However, it is not known whether therapeutic anticoagulation affects outcomes after peripheral endovascular intervention. We sought to investigate whether therapeutic anticoagulation after peripheral endovascular intervention is associated with lower risk of major adverse limb events (MALEs) and all-cause mortality. We studied patients who underwent index endovascular intervention for peripheral artery disease in the Vascular Study Group of New England (2010 to 2018). The main exposure was anticoagulation at the time of discharge. Outcomes included patency loss (occlusion or target lesion reintervention), MALE (any major amputation or reintervention), and all-cause mortality. We compared outcomes between patients who received anticoagulation on discharge versus those who did not receive anticoagulation using Kaplan–Meier survival analysis and Cox regression. In the cohort of 6,809 patients, 15% were discharged on an anticoagulant (mostly warfarin). These patients had a higher prevalence of acute or chronic limb ischemia than those not receiving an anticoagulant (74% vs 47%, p < 0.001) and were less likely to receive any antiplatelet agent after peripheral endovascular intervention (5% vs 14%, p < 0.001). After risk adjustment, compared with patients not on an anticoagulant, patients receiving therapeutic anticoagulation had a higher risk of 2-year patency loss (hazard ratio [HR] 1.41, 95% confidence interval [CI] 1.05 to 1.89), MALE (HR 1.39, 95% CI 1.09 to 1.76), and all-cause mortality (HR 1.24, 95% CI 1.05 to 1.47). In conclusion, anticoagulation after peripheral endovascular intervention was associated with higher risk of adverse events, including patency loss, MALE, and all-cause mortality.